Roche Holding AG

Type: Company
Name: Roche Holding AG (Roche Holding Ltd)
Nationality: Switzerland
Web Address: http://www.roche.com/
Fact Sheet: Fact Sheet for Roche Holding AG
First reported Sep 29 2014 - Updated 1 hour ago - 3 reports

Roche reports positive data from new melanoma therapy trial

:13 in Pharmaceutical Company Product News Roche has announced positive results from a phase III trial that demonstrates the benefits of a combination melanoma therapy utilising cobimetinib plus Zelboraf. Data from the coBRIM study revealed that people ... [Published Zenopa - 1 hour ago]
First reported 2 hours ago - Updated 2 hours ago - 2 reports

WuXi PharmaTech Announces Appointment of William R. Keller to Board

SHANGHAIMr. Keller was the general manager of Roche China Ltd. and Shanghai Roche Pharmaceutical Ltd. from 1994 to 2003, and he served in various positions at Roche Group in South America"I am delighted to join the board of WuXi PharmaTech, the leading ... [Published Stock Nod - 2 hours ago]
First reported Sep 29 2014 - Updated 6 hours ago - 2 reports

FDA slaps cardiovascular warnings on Roche/Novartis asthma blockbuster Xolair

It was way back in 2009 when the FDA first indicated it was worried about reports of heart attacks and strokes in patients taking Xolair, the asthma treatment co-marketed by Novartis ($NVS) and Roche ($RHHBY). Now the agency is taking action, slapping ... [Published FiercePharma - Sep 29 2014]
First reported Sep 29 2014 - Updated 7 hours ago - 8 reports

Cancer Drug From Roche Shows Promise For Increasing Lifespan

Tweet[embedded content]A cancer drug developed by Swiss drug maker Roche has shown promise in significantly extending the lifespan of the patients treated with it in clinical trials. The cancer drug, named Perjeta, is used to treat cases of advanced metastatic ... [Published Zolmax News - 7 hours ago]
First reported 21 hours ago - Updated 20 hours ago - 2 reports

Research and Markets: North America Autoimmune Diagnostics Market Outlook 2019 Featuring Abbott Autoimmune, Bayer-Schering Pharma, Biogen Idec, Eli Lilly, GSK & Roche

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zrjsn8/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their ... [Published Business Wire Health News - 20 hours ago]
First reported Sep 29 2014 - Updated 23 hours ago - 6 reports

Roche GSK melanoma pill combinations look similar in showdown

Related Biotechnology, Pharmaceutical and Healthcare NewsMADRID (Reuters) - Rival two-pill combinations for melanoma from Roche and GlaxoSmithKline had similarly good results in separate clinical trials, leaving doctors with little to choose between the ... [Published BioPortfolio - 23 hours ago]
First reported Sep 29 2014 - Updated 23 hours ago - 3 reports

ROCHE BEARER SHARE : presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab)

Roche presents preliminary combination data for anti-PDL1 medicine (MPDL3280A) with Avastin (bevacizumab) Early data indicate the combination with Avastin in first line metastatic renal cell carcinoma (mRCC) is safe and well tolerated Monotherapy MPDL3280A ... [Published 4 Traders - 23 hours ago]
First reported Sep 29 2014 - Updated Sep 29 2014 - 4 reports

Roche completed tender offer for USD8.3bn takeover of InterMune

(M&A Navigator via COMTEX News Network) -- 29 September 2014 - Swiss pharmaceutical giant Roche Holding AG (VTX:ROG) today announced the successful completion of the tender offer of its subsidiary Klee Acquisition Corp for all outstanding shares of US ... [Published PredictWallStreet - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 4 reports

Trial Confirms That Perjeta Extends Survival In Metastatic Breast Cancer

In Madrid today, researchers presented new findings on the effectiveness of Perjeta ( pertuzumab , Roche), a monoclonal antibody used in combination with other drugs to treat some types of breast cancer. The updated report on the CLEOPATRA trial  supports ... [Published Forbes.com - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 29 2014 - 3 reports

Failed cancer vaccines might live again with new immune drugs

Some scientists suggest that combining cancer vaccines with checkpoint inhibitors may give the vaccines "a new lease on life" as a potential treatment for the disease, as reported by London South East. Use of cancer vaccines has met with a series of ... [Published FirstWord Pharma - Sep 29 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 3 reports

Gain from adding Roche's Avastin to immune drug unclear

Data presented at the European Society of Medical Oncology (ESMO) congress suggests that it is too early to say whether combining Roche's Avastin with the experimental anti-PD-L1 drug MPDL3280A improves outcomes, as reported Sunday in Yahoo!News. In ... [Published FirstWord Pharma - Sep 28 2014]
First reported Sep 28 2014 - Updated Sep 28 2014 - 1 reports

Roche Drug Extends Patients' Survival

ZURICH—A drug developed by Roche Holding AG extended the lives of patients with an aggressive form of breast cancer by longer than ever before, the company said, a positive move for the Swiss firm as patents on a key oncology drug approach expiry. The ... [Published Atlanta Journal And Constitution - Sep 28 2014]

Quotes

...the potential to impact the lives of millions of people who suffer from the symptoms and burdens of living with this condition," said Mr. Step. "RP-G28 is a truly unique product candidate with a strong clinical foundation, and I look forward to advancing its further development."
...Dr Sandra Horning, chief medical officer and head of global product development at Roche, said: "The coBRIM results are exciting because they support the potential of the combination as a new treatment option for people with BRAF mutation-positive advanced melanoma." These findings were presented by Roche at the European Society for Medical Oncology annual congress, which is taking place in Madrid this week
Dr.J Joseph Kim , Inovio's President and CEO, said: "I'm pleased to welcome Jennifer to Inovio as we advance into phase III and invest in maximizing the commercial opportunity for our innovative pipeline of DNA immunotherapies. Jennifer's significant experience in building successful global franchises coupled with her strong leadership will be a driving force in bringing our immunotherapies to patients who most need them and in growing the company."
"We are very pleased to welcome Mr. Keller to WuXi's board" said Dr. Ge Li

More Content

All (1841) | News (1508) | Reports (1) | Blogs (277) | Audio/Video (1) | Fact Sheets (27) | Press Releases (22)
sort by: Date | Relevance
Frost & Sullivan applauds the diversity of Vent... [Published PR Newswire: Financial Services - 15 mins ago]
Frost & Sullivan applauds the diversity of Vent... [Published Financial Services - 15 mins ago]
Ritter Pharmaceuticals Names Michael D. Step Ch... [Published RCL Advisors - 17 mins ago]
Roche reports positive data from new melanoma t... [Published Zenopa - 1 hour ago]
ASCO 2014 -- Delegate Physicians Rate Influence... [Published Stock Nod - 1 hour ago]
Inovio Pharmaceuticals Appoints Jennifer Laux a... [Published Citybizlist - 2 hours ago]
WuXi PharmaTech Announces Appointment of Willia... [Published Stock Nod - 2 hours ago]
WuXi PharmaTech Cayman : Announces Appointment ... [Published 4 Traders - 2 hours ago]
Adding cediranib to chemotherapy improves progr... [Published Medical News Today - 2 hours ago]
Inovio Pharmaceuticals Appoints Vice President ... [Published KSFY - 2 hours ago]
India's Modi must resist U.S. pressure on drug ... [Published Yahoo! Canada - 3 hours ago]
India's Modi must resist U.S. pressure on drug ... [Published AlertNet - 3 hours ago]
Allakos secures $10 mln [Published PE Hub Blog - 3 hours ago]
PD-1 drugs could end 'decades of silence' in bl... [Published PMLive - 4 hours ago]
Janssen, AZ and Roche at ESMO [Published PMLive - 4 hours ago]
Shanghai Zhangjiang Hi-Tech Park Development Co... [Published China Knowledge Online - 4 hours ago]
Global Microscopic Polyangiitis (MPA) Clinical ... [Published EMAILWIRE.com - 6 hours ago]
Cancer Drug From Roche Shows Promise For Increa... [Published Zolmax News - 7 hours ago]
Genentech unveils OS benefit for Perjeta combo [Published BioPortfolio - 9 hours ago]
3 Pharmaceutical Giants on the Road to Curing C... [Published Healthcare Global - 9 hours ago]
Chinese Regulations on In-Vitro Diagnostic Reag... [Published Bio-Medicine - 10 hours ago]
Chinese Regulations on In-Vitro Diagnostic Reag... [Published PRWeb - 10 hours ago]
ESMO In Brief: PD-1 Updates, Perjeta’s Striking... [Published Health News Daily - 12 hours ago]
Pharmaceutical industry and economic health [Published Business Day Nigeria - 13 hours ago]
Wider use of breast cancer drug urged after ‘un... [Published Irish Examiner - 13 hours ago]
Bristol-Myers' Opdivo Under Review in US, EU fo... [Published Nasdaq - 13 hours ago]
Bristol-Myers' Opdivo Under Review in US, EU fo... [Published Yahoo! Finance - 16 hours ago]
Organovo: Competition And Profit Potential [Published Seeking Alpha - 17 hours ago]
Roche Releases Data from CLEOPATRA Study on Per... [Published Zacks.com - 18 hours ago]
GlaxoSmithKline Needs Healthy Doses Of Good New... [Published Seeking Alpha - 18 hours ago]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Frost & Sullivan applauds the diversity of Vent... [Published PR Newswire: Financial Services - 15 mins ago]
MOUNTAIN VIEW, Calif., Sept. 30, 2014 /PRNewswire/ -- Based on its recent analysis of the oncology tissue diagnostics market, Frost & Sullivan recognizes Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, with the 2014 North American ...
Allakos secures $10 mln [Published PE Hub Blog - 3 hours ago]
Biotechnology company Allakos has secured an additional $10 million investment from current investors to fund the development of an additional therapeutic antibody. All of the company’s current investors participated including Novo Ventures , Alta ...
Research and Markets: North America Autoimmune ... [Published Business Wire Health News - 20 hours ago]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zrjsn8/north_america) has announced the addition of the "North America Autoimmune Diagnostics Market - Growth, Trends And Forecasts (2014 - 2019)" report to their ...
Global Infectious Disease Treatment Market 2014... [Published PR Newswire: Health - Sep 29 2014]
DUBLIN, Sept. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Infectious Disease Treatment Market 2014-2018" report to their offering. Infectious diseases can be caused by various pathogenic microorganisms such ...
Genentech’s Investigational Combination of Cobi... [Published EON Science - Sep 29 2014]
SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
Roche to pay $1.7bn for Seragon [Published Reuters Video: Business - Jul 02 2014]
1

Press Releases

sort by: Date | Relevance
Frost & Sullivan applauds the diversity of Vent... [Published Financial Services - 15 mins ago]
Biotech Advancements in Innovative Cancer Thera... [Published Financial Services - Sep 04 2014]
INTERMUNE SHAREHOLDER ALERT: The Law Offices of... [Published GlobeNewswire: Acquisitions News - Sep 03 2014]
Seragon Pharmaceuticals Inc. Announces Closing ... [Published GlobeNewswire: Acquisitions News - Aug 27 2014]
SHAREHOLDER ALERT: Pomerantz LLP Investigates C... [Published Financial Services - Aug 25 2014]
1 2 3 4 5
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.